What Happened?
Woburn, -based Frequency-Therapeutics Resigned Michael Bookman as General Counsel
About the Company
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
About the Person
Michael Bookman is General Counsel and Secretary at Immuneering. Previously, Michael held various senior legal leadership roles in the industry.
Info Source
News
Short Profile